For this inaugural episode of The Pharma Lab, we wanted to have a detailed discussion around amorphous APIs, why they’re so important, the misconceptions around amorphous materials, and the future of amorphous material development.
So we sat down with Dr. Ann Newman, a Pharmaceutical Consultant at Seventh Street Development Group, and Dr. Kenneth Morris, University Professor Emeritus at Long Island University, for a discussion all about:
- The differences between amorphous and a polymorph
- Why amorphous forms are important for drug product development, and in particular, patient outcomes
- The biggest challenges in dealing with amorphous materials for pharmaceuticals
- What we really need to focus on for the future development of amorphous materials
For more insights into the pharmaceutical industry, subscribe to the show on Apple Podcasts, Spotify, or wherever podcasts are found.
Listening on a desktop & can’t see the links? Just search for The Pharma Lab Show in your favorite podcast player.
So we sat down with Dr. Ann Newman, a Pharmaceutical Consultant at Seventh Street Development Group, and Dr. Kenneth Morris, University Professor Emeritus at Long Island University, for a discussion all about:
- The differences between amorphous and a polymorph
- Why amorphous forms are important for drug product development, and in particular, patient outcomes
- The biggest challenges in dealing with amorphous materials for pharmaceuticals
- What we really need to focus on for the future development of amorphous materials
For more insights into the pharmaceutical industry, subscribe to the show on Apple Podcasts, Spotify, or wherever podcasts are found.
Listening on a desktop & can’t see the links? Just search for The Pharma Lab Show in your favorite podcast player.
The podcast The Pharma Lab Show is embedded on this page from an open RSS feed. All files, descriptions, artwork and other metadata from the RSS-feed is the property of the podcast owner and not affiliated with or validated by Podplay.